The prognosis for malignant melanoma (MM) has been related to different factors such as tumor thickness, 1 invasion level 2 and histological tumor type, 3 although these features are of limited value. 4 The development of metastases to distant sites often leads to a poor prognosis, with reported survival times of less than 1 year. 5 The risk of metastasis has been related to the presence of tumoral cells in peripheral blood. Thus, the possibility of detecting circulating melanoma cells potentially represents a new prognostic marker with which to predict clinical behavior, assess tumor progression and chose appropriate treatments for these patients. 6 The reverse transcriptase-polymerase chain reaction assay (RT-PCR), which is based on the amplification of cellspecific mRNAs, has been used to detect occult metastatic tumor cells in blood using specific markers, and has provided a new approach to the assessment of tumor progression. [7] [8] [9] [10] [11] The tyrosinase gene, which encodes a key enzyme in melanin biosynthesis, is actively expressed only by melanocytic cells, and its expression is not found in normal peripheral blood cells. 12 Therefore, the detection of tyrosinase mRNA in peripheral blood has been proposed to identify circulating MM cells, 13,14 although significant rates of variation have been reported. [15] [16] [17] Further research is needed to assess the clinical validity of this technique.
The prognosis for malignant melanoma (MM) has been related to different factors such as tumor thickness, 1 invasion level 2 and histological tumor type, 3 although these features are of limited value. 4 The development of metastases to distant sites often leads to a poor prognosis, with reported survival times of less than 1 year. 5 The risk of metastasis has been related to the presence of tumoral cells in peripheral blood. Thus, the possibility of detecting circulating melanoma cells potentially represents a new prognostic marker with which to predict clinical behavior, assess tumor progression and chose appropriate treatments for these patients. 6 The reverse transcriptase-polymerase chain reaction assay (RT-PCR), which is based on the amplification of cellspecific mRNAs, has been used to detect occult metastatic tumor cells in blood using specific markers, and has provided a new approach to the assessment of tumor progression. [7] [8] [9] [10] [11] The tyrosinase gene, which encodes a key enzyme in melanin biosynthesis, is actively expressed only by melanocytic cells, and its expression is not found in normal peripheral blood cells. 12 Therefore, the detection of tyrosinase mRNA in peripheral blood has been proposed to identify circulating MM cells, 13,14 although significant rates of variation have been reported. [15] [16] [17] Further research is needed to assess the clinical validity of this technique.
The aim of this study was to evaluate the correlation between the detection of tyrosinase by RT-PCR and the clinical status of MM patients. Furthermore, we attempted to define the clinical relevance of the detection of circulating MM cells by correlating the PCR results with known prognostic criteria such as Breslow thickness and histological type of the primary tumor.
MATERIALS AND METHODS

Patients
Blood samples were obtained over a 2-year period at the Dermatology Service of the University Hospital of Granada from 58 consecutively selected MM patients at the time of primary tumor diagnosis or at relapse. Clinical stage was determined according to the American Joint Committee on Cancer: primary cutaneous tumor (stages I and II), regional skin or lymph node metastasis (stage III), or distant metastatic tumor dissemination (stage IV). All patients gave their written consent after receiving information on the purpose of the blood sampling. The outcome of the PCR analyses did not have any influence on treatment. As negative controls, we used blood from 10 healthy subjects or non-melanoma patients, which was analyzed under identical conditions. As a positive control, we used a lymph node metastasis from a patient with MM.
Blood collection and RNA isolation
Samples of peripheral venous blood from each patient were collected in five 10-mL tubes containing ethylenediamine tetraacetic acid, stored at 4 ° C, and processed on ice within 2-4 h. After centrifugation, the supernatant was collected and treated with 45 mL diethyl pyrocarbonate-treated water (H 2 O-DEP) and 5 mL phosphate-buffered saline (PBS) ( × 10), and then centrifuged at 2500 g for 5 min several times until a peripheral blood lymphocytes cell pellet (PBLC) was obtained. Total RNA was isolated from the cell fraction with the IsoRNA-Fast Plus kit (Master Diagnóstica, Granada, Spain) according to the manufacturer's instructions. The yield and purity of the RNA were determined by UV spectroscopy.
Oligonucleotide primers
Oligonucleotide primers specific for tyrosinase were used according to Smith et al . 12 The primers 5 ′ -TTG GCA GAT TGT CTG TAG CC (sense) and 3 ′ AGG CAT TGT GCA TGC TGC TT (antisense) were chosen to amplify a 284-bp fragment of tyrosinase cDNA. Integrity of the RNA was determined using primers 5 ′ -ATG GAT GAT GAT ATC GCC GCG (sense) and 3 ′ TCT CCA TGT CGT CCC AGT TG (antisense), which amplified a 248-bp fragment of β -actin. 18 
RT-PCR assay
Sensitivity and specificity of the RT-PCR product of tyrosinase was previously determined using the SK-mel 1 cell line. 18 Specificity was established by the size of the fragments (207 bp). The RT-PCR product of tyrosinase showed a sensitivity of up to one cell/10 6 PBLC. 18 Reverse transcription was performed using 1 µ g total RNA. First-strand cDNA was generated with 0. After a hot start (2 min at 94 ° C), 2 units of Taq polymerase (Boehringer Mannheim, Mannheim, Germany) was added, followed by 30 cycles at 94 ° C for 1 min, 58 ° C for 2 min, and 72 ° C for 3 min, then 72 ° C for 7 min. For analysis, 70 µ L of the reaction product was run on a 2% agarose gel and stained with ethidium bromide. The gel was viewed and photographed under UV light. Specificity of the amplified product was established by restriction enzyme digestion. The quality of the mRNA was checked by PCR for β -actin. 18 As a positive control, we used a lymph node metastasis from a patient with MM.
Statistical analysis
For statistical evaluation the Pearson χ 2 -test was used to correlate the PCR results with sex and histological tumor type, and the Mann-Whitney test was used to correlate the PCR results with clinical stage and tumor thickness. A multivariate test using logistic regression analysis (SPSS for Windows) was performed to simultaneously determine the association between the PCR results (dependent variable) and clinical stage, primary melanoma thickness and histological tumor type as independent variables.
RESULTS
Patients
Peripheral blood from a total of 58 patients (33 women, 25 men) with MM in different stages was examined for the presence of tyrosinase transcripts (Table 1) . By clinical stage, the distribution was stages I and II in 14 patients, stage III in 28 patients, and stage IV in 16 patients. The primary tumor was classified as nodular melanoma (NM, n = 19), superficial spreading melanoma (SSM, n = 30), acrolentiginous melanoma (ALM, n = 7), or lentigo maligna melanoma (LMM, n = 2).
Tyrosinase PCR results correlated with clinical stage
No tyrosinase mRNA was detected in any of the 10 healthy control patients. PCR for the positive control resulted in strong specific bands at 284 bp (Fig. 1a) . Positive PCR results (Fig. 1c) were obtained for two of the 14 (14%) patients in stages I and II, and for 20 of the 28 (71%) patients in stage III. The highest positivity rate was seen in stage IV: 14 out of 16 (87%) patients. The detection rate for tyrosinase mRNA in peripheral blood cells correlated significantly with the clinical tumor stage ( P < 0.001). The results of amplification of the β -actin PCR product (control) are also shown in Fig. 1b,d . Figure 2 summarizes the results of tyrosinase PCR in relation to the histological classification of the primary tumor. Percentages of positive PCR results varied considerably between the various types of melanoma (LMM, ALM, SSM and NM). In stages I and II, results were positive for two of 11 patients with SSM. In these stages, all patients with NM and the only patient with ALM were PCR negative. In stage III, five of nine patients with NM, 10 of 14 patients with SSM, four patients with ALM and the only patient with LMM showed positive results. In stage IV, circulating tumor cells were detected in all eight patients with NM, four of five patients with SSM, one of two patients with ALM, and the only patient with LMM. No significant correlation was observed between the PCR results and the histological features of the primary tumor. Our results therefore showed considerable differences in stages III and IV between men and women. However, the correlation between sex and the presence of tyrosinase PCR product did not reach statistical significance. Multivariate analysis to simultaneously consider the association between PCR results (dependent variable) and the clinical data (independent variables) revealed significant differences among various disease (stages I-IV, P ≤ 0.001) and among tumor thickness ( P = 0.005).
Analysis of the correlation between tyrosinase PCR and histological type of primary tumor
DISCUSSION
It has recently been suggested that RT-PCR-based detection of tyrosinase mRNA in peripheral blood might be useful for the early detection of circulating melanoma cells, as tyrosinase is thought to be a melanocyte-specific marker. Previous studies have demonstrated the usefulness of the RT-PCR assay in detecting circulating melanoma cells in peripheral blood, [19] [20] [21] although most studies have compared the PCR findings with clinical stage only. Our study of 58 patients analyzed the correlation between the detection of tyrosinase mRNA and different factors considered to predict the prognosis of melanoma.
The correlation between detection of tyrosinase mRNA in the blood of patients with MM by PCR and the clinical stage is controversial. [22] [23] [24] The discrepant results obtained by different authors may reflect differences in PCR methodology. 25 Our results, obtained with a meticulous PCR technique, established a statistically significant association between the clinical stage of MM and the detection of tyrosinase mRNA in peripheral blood. This finding supports the hypothesis that tyrosinase mRNA is a tumor progression marker in MM, as has been reported previously. 26 Moreover, the highest detection rate was observed in patients with stage IV disease (87%), in agreement with the findings of Mellado et al . 27 and Farthmann et al . 28 However, we found that some patients with stage IV disease were PCR negative, supporting the notion that the existence of distant metastases does not imply the presence of circulating tumor cells detectable in the blood. 29 In our study, the RT-PCR assay for tyrosinase mRNA showed a significant correlation with sex and primary tumor thickness. Tyrosinase was found more frequently in men than in women with MM; interestingly, epidemiological data show that the prognosis for MM tends to be better in women. 30 Our results also showed that a positive PCR result was most frequent in primary tumors > 4 mm thick than in those measuring < 4 mm. These data coincide with a higher risk of progression in patients with thick primary melanomas. 1 Nonetheless, even thin melanomas measuring ≤ 1 mm may shed tyrosinase-positive cells into the bloodstream. However, in contrast with Farthmann et al. 28 we found no significant correlation between PCR positivity and the histological type of melanoma. This finding may be related to the small number of patients in our sample with each particular histological type of tumor, as this made it difficult to establish significant correlations.
We evaluated the correlation between the detection of the tyrosinase mRNA by RT-PCR and different prognostic crite- Further studies will attempt to define the significance of the presence of circulating tyrosinase mRNA for the prognosis in patients with MM, and the value of PCR in monitoring the effectiveness of melanoma therapy.
